Correction to: Trials (2020) 21:835
https://doi.org/10.1186/s13063-020-04769-2
Following publication of the original article [1], we were notified that in the first paragraph of the Interventions section (line 202), “Participants randomized to placebo will be administered 288 mg of rice protein, 133.4 mg microcrystalline cellulose” should read “Participants randomized to placebo will be administered 288 mg of rice protein,109.3 mg microcrystalline cellulose”.
The original article has been corrected.
Reference
Bradley R, et al. Xanthohumol microbiome and signature in healthy adults (the XMaS trial): a phase I triple-masked, placebo-controlled clinical trial. Trials. 2020;21:835. https://doi.org/10.1186/s13063-020-04769-2.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Bradley, R., Langley, B.O., Ryan, J.J. et al. Correction to: Xanthohumol microbiome and signature in healthy adults (the XMaS trial): a phase I triple-masked, placebo-controlled clinical trial. Trials 21, 885 (2020). https://doi.org/10.1186/s13063-020-04834-w
Published:
DOI: https://doi.org/10.1186/s13063-020-04834-w